Denali Therapeutics Inc.
Denali Therapeutics Inc. (DNLI) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DNLI · as of Sep 30, 2025
Ownership Breakdown
243
Institutional Holders
▲ 9 vs Q2
$1.97B
Total Inst. Value
▲ $42.78M vs Q2
158.71M
Shares Outstanding
freeFloat 90.90%
135.53M
13F Shares Held
▼ 2.07M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DNLI largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 12.29M | 7.17% | 7.17% | $178.45B | Nov 12, 2025 | ▲ 236.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 11.99M | 7.00% | 7.00% | $174.14B | Nov 7, 2025 | ▲ 182.2K |
BAILLIE GIFFORD & CO biological products, (no diagnostic substances) | 11.59M | 6.76% | 6.76% | $168.31B | Oct 31, 2025 | ▼ 363.7K |
FMR LLC biological products, (no diagnostic substances) | 6.34M | 3.70% | 3.70% | $92.06B | Nov 13, 2025 | ▼ 1.20M |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 5.64M | 3.29% | 3.29% | $81.87B | Nov 14, 2025 | ▲ 2.39M |
UBS ASSET MANAGEMENT AMERICAS INC biological products, (no diagnostic substances) | 5.47M | 3.19% | 3.19% | $79.35B | Nov 14, 2025 | ▼ 797.2K |
STATE STREET CORP biological products, (no diagnostic substances) | 5.46M | 3.19% | 3.19% | $79.34B | Nov 14, 2025 | ▲ 946.3K |
TEMASEK HOLDINGS (PRIVATE) LTD biological products, (no diagnostic substances) | 5.36M | 3.12% | 3.12% | $77.77B | Nov 14, 2025 | — held |
CAPITAL RESEARCH GLOBAL INVESTORS biological products, (no diagnostic substances) | 4.76M | 2.78% | 2.78% | $69.13B | Nov 13, 2025 | ▲ 10.3K |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 4.57M | 2.66% | 2.66% | $66.33B | Nov 14, 2025 | ▼ 2.01M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
31
Increased
+12.65M shares1
New Positions
first time holders12
Decreased
−6.20M shares0
Sold Out
fully exitedNet shares change (top 50)
+6.46M
+12.65M / −6.20M
Net new holders
+20
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DNLI insider trading · insider activity
Source: SEC Form 4
18
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
FLATLEY JAY T director | Jun 3, 2026 | Award | 6,408 | — | — | 22.6K | Form 4 ↗ |
FLATLEY JAY T director | Jun 3, 2026 | Award | 19,226 | $19.66 | $378.0K | 19.2K | Form 4 ↗ |
Klein Peter S director | Jun 3, 2026 | Award | 6,408 | — | — | 33.9K | Form 4 ↗ |
Klein Peter S director | Jun 3, 2026 | Award | 19,226 | $19.66 | $378.0K | 19.2K | Form 4 ↗ |
Krognes Steve E. director | Jun 3, 2026 | Award | 6,408 | — | — | 38.2K | Form 4 ↗ |
Krognes Steve E. director | Jun 3, 2026 | Award | 19,226 | $19.66 | $378.0K | 19.2K | Form 4 ↗ |
Schenkein David P director | Jun 3, 2026 | Award | 6,408 | — | — | 21.7K | Form 4 ↗ |
Schenkein David P director | Jun 3, 2026 | Award | 19,226 | $19.66 | $378.0K | 19.2K | Form 4 ↗ |
Thornberry Nancy director | Jun 3, 2026 | Award | 6,408 | — | — | 31.1K | Form 4 ↗ |
Thornberry Nancy director | Jun 3, 2026 | Award | 19,226 | $19.66 | $378.0K | 19.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Denali Therapeutics Inc. (DNLI) is primarily owned by institutional investors, who hold approximately 85.4% of total shares outstanding. Company insiders own approximately 9.10%, while retail and public investors account for the remaining 5.51%.
The largest institutional shareholder of Denali Therapeutics Inc. is BLACKROCK, INC., holding approximately 12.29 million shares — equal to 7.17% of outstanding shares — as of September 30, 2025.
A total of 243 institutional investors currently hold DNLI stock, with a combined institutional value of approximately $1.97 billion as of the most recent 13F filing period.
Frequently asked questions
DNLI ownershipDenali Therapeutics Inc. (DNLI) is primarily owned by institutional investors, who hold approximately 85.4% of shares. The largest shareholder is BLACKROCK, INC. with a 7.17% stake. Company insiders hold 9.10%. Data sourced from SEC Form 13F as of September 30, 2025.